Is it Time to Dump BioXcel Therapeutics Inc (BTAI) Stock After it Is Lower By 1.08% in a Week?

BioXcel Therapeutics Inc (BTAI) stock is lower by 1.08% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

BioXcel Therapeutics Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on BTAI!

See Full BTAI Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With BTAI Stock Today?

BioXcel Therapeutics Inc (BTAI) stock is trading at $2.74 as of 3:16 PM on Tuesday, Mar 19, of $0.00, or 0% from the previous closing price of $2.74. Volume today is light. So far 348,156 shares have traded compared to average volume of 2,707,021 shares. The stock has traded between $2.64 and $2.85 so far today. To see InvestorsObserver's Sentiment Score for BioXcel Therapeutics Inc click here.

More About BioXcel Therapeutics Inc

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501, and BXCL701. Click Here to get the full Stock Report for BioXcel Therapeutics Inc stock.